For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 16,720,362 | 8,035,969* | 6,291,171 | 5,161,921 |
| General and administrative | 1,291,820 | 1,099,647* | 1,143,804 | 1,109,532 |
| Total operating expenses | 18,012,182 | 9,135,616 | 7,434,975 | 6,271,453 |
| Operating loss | -18,012,182 | -9,135,616* | -7,434,975 | -6,271,453 |
| Interest income | 137,800 | 183,493* | 152,317 | 191,395 |
| Change in fair value of warrants | 268,000 | 322,000* | 20,000 | -140,000 |
| Total other income, net | 405,800 | 505,493* | 172,317 | 51,395 |
| Net loss | -17,606,382 | -8,630,123 | -7,262,658 | -6,220,058 |
| Basic EPS | -0.63 | -0.384 | -0.37 | -0.32 |
| Diluted EPS | -0.63 | -0.384 | -0.37 | -0.32 |
| Basic Average Shares | 27,847,884 | 22,484,689 | 19,685,071 | 19,486,231 |
| Diluted Average Shares | 27,847,884 | 22,484,689 | 19,685,071 | 19,486,231 |
Annovis Bio, Inc. (ANVS)
Annovis Bio, Inc. (ANVS)